

結腸がんに対する補助療法の改善 (Abstract LBA1)

結腸がん術後補助化学療法に対する個別化治療のためのリスクに基づく新たな標準治療が世界的研究により定められた

Global study sets new risk-based standard to personalize chemotherapy for colon cancer after surgery

リンパ節転移陽性結腸がん(ステージIII)に対する術後補助化学療法は、一部の患者では長期にわたる標準コースの半分しか必要でない可能性がある、と2017年American Society of Clinical Oncology年次集会で発表された。北米、ヨーロッパ、およびアジアにおける6つの臨床試験の解析において、比較的再発リスクの低い患者では3か月間の化学療法は6か月間の化学療法と同様に有効であった。3か月の治療レジメンはまた、副作用、特に神経障害が少なかった。筆者らは、再発リスクの低い60%の患者にとって3か月の化学療法は新たな標準治療となるであろう、と示唆している。

Full Text

After surgery for lymph-node positive colon cancer (stage III), some patients may only need half of the long-standing standard course of chemotherapy. In an analysis of six clinical trials with over 12,600 patients, three months of chemotherapy was nearly as effective as six months in patients with relatively lower recurrence risk and caused fewer side effects, particularly nerve damage.

These data were presented in ASCO's Plenary Session, which features four abstracts deemed to have the greatest potential to impact patient care, out of the more than 5,000 abstracts featured as part of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.

Chemotherapy lowers the chance of cancer recurrence after colon cancer surgery. Since 2004, the standard adjuvant treatment has been a combination of chemotherapies (FOLFOX or CAPOX), given over a period of six months. The goal of this study, which pooled data from 6 studies conducted in North America, Europe, and Asia, was to determine if three months of chemotherapy was as effective as 6 months. While the primary endpoint was not proven statistically, a shorter, 3-month course of chemotherapy was associated with a less than 1% lower chance of being colon cancer free at three years compared to the standard 6-month course (74.6% vs. 75.5%). In patients considered at low risk of cancer recurrence (60% of patients in the study), the difference was even smaller (83.1% in patients receiving a 3-month course vs. 83.3% in patients receiving a 6-month course).

"Our findings could apply to about 400,000 colon cancer patients worldwide every year. For 60% of these patients, who have lower risk for cancer recurrence, three months of chemotherapy will likely become the new standard of care," said senior study author Axel Grothey, MD, an oncologist at the Mayo Clinic Cancer Center in Rochester, Minnesota. "Patients with higher risk colon cancer, however, should discuss these results with their doctor to see if a shorter course of therapy would be right for them, taking into account their preference, age, and ability to tolerate chemotherapy."

A key side effect of one of the chemotherapies in the regimen – oxaliplatin – is nerve damage, which can result in permanent numbness, tingling, and pain. The longer a patient receives oxaliplatin, the greater the chance for severe and long-lasting nerve damage. Nerve damage (numbness/tingling of the hands and feet) was substantially less common in patients receiving a 3-month course of chemotherapy vs. a 6-month month course (15% vs. 45% with FOLFOX and 17% vs. 48% with CAPOX).

"Many side effects of chemotherapy, such as hair loss, go away over time, but nerve damage is a side effect some patients have to deal with for the rest of their lives," said Dr. Grothey.

This study is a prospective, pre-planned analysis of pooled data from six concurrent, phase III clinical trials conducted in 12 countries. It was established more than 10 years ago as so-called IDEA collaboration (International Duration Evaluation of Adjuvant therapy). A steering committee oversaw the study design, and an independent statistical center reviewed the results from all six clinical trials (findings from three of which are being presented at the ASCO Annual Meeting). The study received public funding only.

"We needed this large number of patients to answer the study question, but at the time this study began in 2007 it was not possible to run one study of that size anywhere in the world," said Dr. Grothey. "With more than 12,834 patients, this is the largest collaboration of its kind in oncology."

Patients were followed for a median time of 39 months. For all patients combined, the rate of disease-free survival at three years was slightly lower with three months of chemotherapy than with six months of chemotherapy (74.6% vs. 75.5%). The type of chemotherapy regimen selected affected the difference in 3-year disease-free survival between the 3-month and 6-month treatment duration (75.9% vs. 74.8% with CAPOX and 73.6% vs. 76.0% with FOLFOX), although the difference was relatively small in both cases.

In the subset of patients with lower risk colon cancer (defined as cancer spread to 1-3 lymph nodes and not completely through the bowel wall), the disease-free survival rate at three years was almost identical for those who received 3 (83.1%) and 6 months of chemotherapy (83.3%).

The rate of clinically meaningful (grade 2 or greater) nerve damage differed depending on the type of chemotherapy regimen received, but was consistently higher for people who received 6 months versus 3 months of chemotherapy (45% vs. 15% with FOLFOX and 48% vs. 17% with CAPOX).

"Aside from nerve damage, longer chemotherapy also means more diarrhea and fatigue, more doctor appointments, blood draws, and time away from work and social interactions," said Dr. Grothey.

"This is extremely important work that will affect the lives of many of my patients hopefully tomorrow, and will allow us to provide a more personalized approach to our patients with colon cancer. Although addressing the question, 'can we give less treatment?' is of major importance to patients and their doctors, it is rare to see this type of study. Given that these questions are unlikely to be of interest to the pharmaceutical industry, federal support for these trials is critical," said Dr. Baxter.

"In this case, less is more. We're now able to spare many patients with colon cancer unnecessary side effects of an additional three months of chemotherapy without compromising results. This study is an excellent example of how existing treatments can be refined to work even better for patients," said ASCO Expert Nancy Baxter, MD.

This study was funded by grants from the Medical Research Council, National Institute for Health Research, National Cancer Institute, Italian Agency for Drugs (AIFA), Japanese Foundation for Multidisciplinary Treatment of Cancer, French Ministry of Health, and French National Cancer Institute (Inca).

ASCO2017特集

[News 01]

ナッツの摂取が大腸がん再発リスクを低下させる

[News 02]

胆管がん患者の生存期間延長

[News 03]

分子標的治療は肺がんの再発を遅延させる

[News 04]

結腸がん治療後の健康的なライフスタイルは生存率を改善する

[News 05]

ワクチン使用による経口HPV感染の軽減

[News 06]

結腸がんに対する補助療法の改善

[News 07]

症状を自己報告するウェブベースのシステムは患者の生存期間延長に役立つ

[News 08]

OlaparibはBRCA関連転移性乳がんの増殖を遅延させる

[News 09]

多発性骨髄腫に対する新たなタイプの免疫療法

[News 10]

EGFR遺伝子変異陽性肺がんの新たな治療の可能性

[News 11]

アレクチニブは肺がんの無増悪生存期間を改善する

[News 12]

浸潤性乳がんのリスクを低下させる

[News 13]

新規診断転移性前立腺がんにおける予後の改善

[News 14]

Larotrectinibは多様な腫瘍タイプに効果的である

[News 15]

短期および長期の放射線治療は患者の可動性を維持するのに役立つ

[News 16]

胸膜中皮腫に対する初めての免疫療法の兆しが見える

[News 17]

心理的介入はがん患者の苦悩を緩和する

[News 18]

乳がん罹患後の妊娠は再発率を上昇させない

[News 19]

精巣腫瘍による性腺機能低下症は慢性的な健康問題と関連がある

[News 20]

心理的介入はがん再発の恐怖を軽減する